In a recent study published in the journal Cell, researchers investigated the infectivity, fusogenicity, and immune evasive potential of two novel Omicron subvariants – BA.2.86 and FLip. They used ...

The realistic goal of vaccine-or-test requirements announced Wednesday by St. Paul and Minneapolis isn’t to crush the coronavirus. Or promptly end the strain on hospitals. Or even to make restaurants, ...

Add Yahoo as a preferred source to see more of our stories on Google. NEW BRUNSWICK, NJ — Researchers at Rutgers say they have developed a test that can specifically identify the omicron variant of ...

Speed is everything in the race against COVID-19’s Omicron variant, the fastest version of the virus we’ve seen to date. Its dizzying rise to dominance in the United States threatens to overwhelm our ...

As the omicron variant continues to sweep the United States, the FDA is being urged to gather more information about how well at-home Covid tests are able to detect the modified virus. Mounting ...

Vaccine makers Pfizer and BioNTech announced plans early Tuesday to test an omicron-specific COVID-19 vaccine in people. The companies will run three simultaneous trials in adults ages 18-55 to ...

As the Omicron surge drives infection rates to record highs, testing has emerged as an essential tool for limiting its spread. But over the last month, laboratories and manufacturers have struggled to ...

Pfizer is enrolling healthy adults to test a reformulated COVID-19 vaccine that matches the hugely contagious omicron variant, to see how it compares with the original shots. Pfizer and its partner ...

You've tested negative for COVID using a rapid antigen test (RAT), but are a close contact of a positive family member and have symptoms. So you might be wondering if you're really COVID-negative or ...

Official COVID-19 case metrics severely undercount the true number of infections, leaving the United States with a critical blind spot as the most transmissible coronavirus variant yet takes hold. The ...

Pfizer and BioNTech will run three simultaneous trials in adults ages 18-55 to determine if an omicron-specific vaccine is more effective than current shots. The two-dose Comirnaty vaccine has been ...